About the company

PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform. The company was founded in 2006 and is based in Fujisawa, treating Japan.